Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

医学 乳腺癌 癌症研究 癌症 肿瘤科 转移性乳腺癌 富维斯特朗 帕博西利布 内科学 靶向治疗 转移 后天抵抗
作者
Utthara Nayar,Ofir Cohen,Christian Kapstad,Adrienne G. Waks,Seth A. Wander,Corrie A. Painter,Samuel S. Freeman,Priyanka Ram,Nicole S. Persky,Lori Marini,Karla Helvie,Nelly Oliver,Cynthia X. Ma,Eric P. Winer,Nan Lin,Nikhil Wagle
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78: 4952-4952 被引量:3
标识
DOI:10.1158/1538-7445.am2018-4952
摘要

Despite the reduction in cancer recurrence and mortality provided by therapies that target the estrogen receptor (ER), resistant ER+ breast cancer remains the most common cause of breast cancer death. Beyond mutations in ER in 25-30% of patients treated with aromatase inhibitors, which deplete circulating estrogen, our understanding of clinical mechanisms of resistance to agents that target the ER remains incomplete. We used whole exome sequencing (WES) of metastatic biopsies to identify mechanisms of resistance in patients with ER+ metastatic breast cancer (MBC) who had developed resistance to ER-directed agents, including aromatase inhibitors, tamoxifen, and fulvestrant. We noted mutations in human epidermal growth factor receptor 2 (HER2) in metastatic biopsies from 12 patients out of 168. Of these, eight mutations had previously been described as activating. Examination of the treatment-naive primary tumors in the five patients with activating mutants where WES from the matched treatment-naive primary tumor was available revealed no evidence of pre-existing mutations in four of the five patients, suggesting that these four mutations were acquired under the selective pressure of ER-directed therapy. These acquired HER2 mutations were mutually exclusive with ER mutations, suggesting a distinct mechanism of resistance to ER-directed therapies. In vitro analysis through expression in ER+/HER2- cell lines confirmed that these mutations conferred estrogen independence. In addition, and in contrast to ER mutations, these HER2 mutations resulted in resistance to tamoxifen, fulvestrant, and the CDK4/6 inhibitor palbociclib. The mutants result in increased AKT and ERK phosphorylation in ER+ cell lines, while simultaneously repressing ER levels and ER-dependent transcriptional targets. One mutation observed in two patients, S653C, occurring in the transmembrane domain and not previously observed in breast cancer, was shown to likely function through constitutive dimerization, a mechanism of activation not previously described for this mutation. Resistance caused by all four mutations was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor neratinib, suggesting a novel effective treatment strategy in these patients. Thus, we have shown that acquired activating HER2 mutations can confer endocrine resistance in ER+/HER2- breast cancer, and that such resistance can be effectively reversed by combination therapies that include an anti-HER2 inhibitor. Citation Format: Utthara Nayar, Ofir Cohen, Christian Kapstad, Adrienne Waks, Seth A. Wander, Corrie Painter, Samuel Freeman, Priyanka Ram, Nicole Persky, Lori Marini, Karla Helvie, Nelly Oliver, Cynthia X. Ma, Eric P. Winer, Nancy U. Lin, Nikhil Wagle. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4952.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CZY完成签到,获得积分10
刚刚
Jie发布了新的文献求助10
刚刚
刚刚
三月发布了新的文献求助10
刚刚
小羊兜兜完成签到,获得积分10
刚刚
WXD发布了新的文献求助10
1秒前
科研通AI6.2的应助被紧张的海采纳,获得10
1秒前
2秒前
huhu发布了新的文献求助10
2秒前
WWJ完成签到 ,获得积分10
2秒前
黃偉倫的应助被xinanan采纳,获得10
2秒前
2秒前
3秒前
在水一方的应助被tong采纳,获得10
3秒前
3秒前
文静的灵煌完成签到,获得积分10
3秒前
小马过河发布了新的文献求助10
4秒前
4秒前
4秒前
fortuna发布了新的文献求助10
4秒前
鼠苑完成签到 ,获得积分10
4秒前
4秒前
小马甲的应助被江北第一深情采纳,获得10
5秒前
CodeCraft的应助被xzzz采纳,获得10
5秒前
土豆饼完成签到,获得积分20
6秒前
6秒前
6秒前
luoluo发布了新的文献求助10
7秒前
luo完成签到 ,获得积分10
7秒前
职克琪发布了新的文献求助10
7秒前
7秒前
8秒前
jksg发布了新的文献求助30
8秒前
8秒前
Zyou发布了新的文献求助10
9秒前
9秒前
王抗抗发布了新的文献求助10
9秒前
NASA_FAST发布了新的文献求助30
9秒前
呜呼完成签到,获得积分10
10秒前
茶泡饭发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161749
求助须知:如何正确求助?哪些是违规求助? 9556240
关于积分的说明 21733360
捐赠科研通 7751657
什么是DOI,文献DOI怎么找? 3427566
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472047